Please read this! Someone (we have our suspicions) from BTA has been tweeted alarming things recently and is causing outrage amongst thyroid patients. It is on the Thyroid Patients Canada Facebook page, for this on FB. I've copied it here:
Recently on Twitter, The British Thyroid Association (BTA) has engaged in demeaning, unprofessional metaphors, comparing LT3 (liothyronine, T3) and LT4 (levothyroxine) hormone treatment to "deluxe" vs. "supasaver" ginger cookies.
This is unprecedented incivility of physicians toward their most vulnerable patients. A comparison of LT3 and LT4 to cookies is entirely inappropriate for a life-sustaining treatment of a vital disability.
This is an example of what our patient organization stands against: "Thyroid pharmaceutical prejudice."
When people show open prejudice against any thyroid treatment at any ratio of T4 to T3, they are indirectly attacking the patients who require that treatment and do not fare well on any other.
Here is some of the context leading up to the BTA's ginger cookie quip.
On Nov 18, Antonio Bianco posted a study of LT3 saying "Provocative Norwegian randomized crossover study comparing mono-therapy with LT4 vs. LT3 in 59 women with residual hypothyroid symptoms. The use of LT3 for 3 months improved QoL without biochemical or clinical signs of thyrotoxicosis (most preferred LT3)."
Then BTA replied to Bianco: "Big proviso: the study is unblinded and QoL is the outcome. This is how supermarkets do research; scientists need to raise their game."
Then on Nov 19, Linda Sanday said "If supermarkets are as successful in teasing out essential details of customers preferences (QoL) as they appear to be, who says the science of blinding is necessary for finding truths?"
Then in reply to Linda, out of the blue, LT3 patients get this attack from the BTA:
"Except you’re not asking 30 million taxpayers to fund your deluxe organic stem ginger cookies when the evidence shows that supasaver ginger snaps work exactly the same and are probably safer."
... By saying "your deluxe organic stem ginger cookies," they are implying that Linda is a user of LT3 hormone, and she is asking taxpayers to fund her unnecessary and potentially dangerous treatment.
In the UK, thyroid treatment is funded by the National Health Service (NHS), which is taxpayer-funded but struggling to make ends meet. More than a decade ago, there was a huge price hike of LT3. The price has not yet come down to reasonable levels. Therefore, LT3 treatment comes at a high price to UK taxpayers in comparison to cheaper LT4 hormone.
Today, not only are UK regional health care units reluctant to permit patients to start LT3, they may attempt to take their LT3 away completely.
The BTA spokespeople are showing how they disparage thyroid patients who suffer poor health on their preferred LT4 monotherapy. It's not our fault if some of us fail the LT4 clinical trial they have forced on us without our consent.
It was their opinion-based choice, as a medical discipline of endocrinology, to remove T3 from thyroid therapy in the 1980s and 1990s, without any double blind clinical trials proving that removing T3 was "safe" for all hypothyroid patients.
To defend that non-evidence-based decision by attacking the only alternative (a return to T3-inclusive treatment), is to defend a huge historic mistake.